SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-18-008658
Filing Date
2018-11-06
Accepted
2018-11-06 17:01:33
Documents
70
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20180930x10q.htm 10-Q 2164896
2 EX-31.1 acrs-20180930ex3117b7d9c.htm EX-31.1 17125
3 EX-31.2 acrs-20180930ex312008dd4.htm EX-31.2 17111
4 EX-32.1 acrs-20180930ex321879c9d.htm EX-32.1 10658
  Complete submission text file 0001558370-18-008658.txt   8272650

Data Files

Seq Description Document Type Size
5 EX-101.INS acrs-20180930.xml EX-101.INS 1989646
6 EX-101.SCH acrs-20180930.xsd EX-101.SCH 47181
7 EX-101.CAL acrs-20180930_cal.xml EX-101.CAL 51587
8 EX-101.DEF acrs-20180930_def.xml EX-101.DEF 177621
9 EX-101.LAB acrs-20180930_lab.xml EX-101.LAB 507061
10 EX-101.PRE acrs-20180930_pre.xml EX-101.PRE 339859
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 181163826
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1